Browse by Audience
Skip to content
Papers of the Week
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
Abstract
8-week glecaprevir/pibrentasvir demonstrates high rates of sustained virological response at post-treatment week 12 (SVR12) across hepatitis C virus (HCV) genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated glecaprevir/pibrentasvir once daily for 8 weeks in treatment-naïve patients with compensated cirrhosis.